Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis

• Published in: Frontiers in cardiovascular medicine Vol. 8; p. 754784
• Main Authors: Kobayashi, Masatake, Ferreira, Maria Betânia, Costa, Rita Quelhas, Fonseca, Tomás, Oliveira, José Carlos, Marinho, António, Carvalho, Henrique Cyrne, Girerd, Nicolas, Rossignol, Patrick, Zannad, Faiez, Rodrigues, Patrícia, Ferreira, João Pedro
• Format: Journal Article
• Language: English
• Published: Frontiers Media 18.11.2021; Frontiers Media S.A
• Subjects: Cardiology and cardiovascular system; Cardiovascular Medicine; circulating biomarkers; echocardiogram; heart failure with preserved ejection fraction; Human health and pathology; Life Sciences; prognosis; rheumatoid arthritis; heart failure with preserved ejection fraction; circulating biomarkers; rheumatoid arthritis; prognosis; echocardiogram
• DOI: 10.3389/fcvm.2021.754784
• ISSN: 2297-055X

Background: Rheumatoid arthritis (RA) increases the risk for abnormalities of the cardiac structure and function, which may lead to heart failure (HF). Studying the association between circulating biomarkers and echocardiographic parameters is important to screen patients with RA with a higher risk of cardiac dysfunction. Aim: To study the association between circulating biomarkers and echocardiographic parameters in patients with RA. Methods: Echocardiography was performed in 355 patients with RA from RA Porto cohort and the associations between echocardiographic characteristics and 94 circulating biomarkers were assessed. These associations were also assessed in the Metabolic Road to Diastolic Heart Failure (MEDIA-DHF) [392 patients with HF with preserved ejection fraction (HFpEF)] and the Suivi Temporaire Annuel Non-Invasif de la Santé des Lorrains Assurés Sociaux (STANISLAS) (1,672 healthy population) cohorts. Results: In the RA Porto cohort, mean age was 58 ± 13 years, 23% were males and mean RA duration was 12 ± 10 years. After adjustment and multiple testing correction, left ventricular mass index (LVMi), left atrial volume index (LAVi), and E/e′ were independently associated with biomarkers reflecting inflammation [i.e., bone morphogenetic protein 9 (BMP9), pentraxin-related protein 3 (PTX3), tumor necrosis factor receptor superfamily member 11a (TNFRSF11A)], extracellular matrix remodeling [i.e., placental growth factor (PGF)], congestion [i.e., N-terminal pro-brain natriuretic peptide (NT-proBNP), adrenomedullin (ADM)], and myocardial injury (e.g., troponin). Greater LVMi [hazard ratio (HR) (95% CI) per 1 g/m 2 = 1.03 (1.02–1.04), p < 0.001], LAVi [HR (95% CI) per 1 ml/m 2 = 1.03 (1.01–1.06), p < 0.001], and E/e′ [HR (95% CI) per 1 = 1.08 (1.04–1.13), p < 0.001] were associated with higher rates of cardiovascular events. These associations were externally replicated in patients with HFpEF and asymptomatic individuals. Conclusion: Circulating biomarkers reflecting inflammation, extracellular matrix remodeling, congestion, and myocardial injury were associated with underlying alterations of cardiac structure and function. Biomarkers might be used for the screening of cardiac alterations in patients with RA.